180 related articles for article (PubMed ID: 19760239)
1. Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents.
Hoppe H; Spagnuolo S; Froehlich JM; Nievergelt H; Dinkel HP; Gretener S; Thoeny HC
Eur Radiol; 2010 Mar; 20(3):595-603. PubMed ID: 19760239
[TBL] [Abstract][Full Text] [Related]
2. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
3. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
Starekova J; Bruce RJ; Sadowski EA; Reeder SB
Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
Tsushima Y; Kanal E; Thomsen HS
Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
[TBL] [Abstract][Full Text] [Related]
7. The use of gadolinium for arterial interventions.
Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC
Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis.
Bardin T; Richette P
Curr Opin Rheumatol; 2010 Jan; 22(1):54-8. PubMed ID: 19881349
[TBL] [Abstract][Full Text] [Related]
9. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
10. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
[TBL] [Abstract][Full Text] [Related]
11. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
Gauthier ID; Macleod CA; Sathiadoss P; McGrath TA; Nair V; Schieda N
Abdom Radiol (NY); 2022 Mar; 47(3):1196-1201. PubMed ID: 34997298
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
[TBL] [Abstract][Full Text] [Related]
15. [Gadolinium-enhanced thoracic CTA: retrospective analysis of image quality and tolerability in 45 patients evaluated prior to the description of nephrogenic systemic fibrosis].
Smadja L; Rémy-Jardin M; Dupuis P; Deken-Delannoy V; Devos P; Duhamel A; Laffitte JJ; Dequiedt P; Rémy J
J Radiol; 2009 Mar; 90(3 Pt 1):287-98. PubMed ID: 19421113
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
17. [Kidney and iodinated and gadolinium-based contrast agents].
Clément O; Faye N; Fournier L; Siauve N; Frija G
J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis following gadolinium administration.
Tammaro A; Narcisi A; Tuchinda P; Sina B
Cutis; 2015 Jul; 96(1):E23-5. PubMed ID: 26244362
[No Abstract] [Full Text] [Related]
19. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
Semelka RC; Prybylski JP; Ramalho M
Magn Reson Imaging; 2019 May; 58():174-178. PubMed ID: 30471330
[TBL] [Abstract][Full Text] [Related]
20. [Nephrogenic systemic fibrosis and use of MR contrast media].
Christiansen RE; Sviland L; Sekse I; Svarstad E
Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
